Nota: La página que ha solicitado no está en su idioma predeterminado. Usted está usando nuestra plataforma en otro idioma ahora.
This statistic shows the total assets of the French pharmaceutical group Ipsen from 2014 to 2019 in million euros. The total assets of the group had a value of approximately 4.3 billion euros in 2019. This figure increased compared to 2017 and 2018, as the total assets then reached 3.1 and 3.4 billion euros respectively.
Total assets of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Total equity of the Ipsen group 2014-2019
- Premium Statistic Total liabilities of the Ipsen group 2014-2019
- Premium Statistic Global revenue in general medicine of the Ipsen group 2014-2019
- Premium Statistic Commercial expenses of the Ipsen group 2014-2019
- Premium Statistic Research and development expenditure of the Ipsen group 2014-2019
- Premium Statistic Operating profit of the Ipsen group 2014-2019
- Premium Statistic Consolidated net profit of the Ipsen group 2014-2019
- Premium Statistic Global revenue in specialty medicine of the Ipsen group 2014-2019
- Premium Statistic Global revenue of the Ipsen group 2019, by geographical area
- Premium Statistic Global revenue of the Ipsen group 2014-2019
About the region
10
- Basic Statistic Ipsen group sales 2019, by therapeutic area
- Basic Statistic Medication sales of the Ipsen Group 2019
- Premium Statistic Top global companies by orphan drug revenues 2023
- Basic Statistic Orphan drug sales worldwide by therapy category 2028
- Basic Statistic Orphan vs. non-orphan pipeline sales forecast worldwide 2023-2028
- Basic Statistic Top drugs based on projected 2024 global sales
- Basic Statistic Worldwide Rx drug sales excluding generics and orphan drugs 2012-2026
- Premium Statistic Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Premium Statistic Share of Takeda's sales after Shire deal 2019 by region
- Basic Statistic Takeda new debts to EBITDA ratios targeted until 2023
Selected statistics
5
- Premium Statistic Expenditure worldwide on diabetes by market 2013-2018
- Premium Statistic Medicinal market growth worldwide including rebates 2009-2018
- Basic Statistic AstraZeneca's revenue from top product Pulmicort 2006-2023
- Premium Statistic Chinese insulin market distribution: leading companies 2011
- Premium Statistic U.S. insulin market distribution: leading companies 2011
Other regions
10
- Basic Statistic Top U.S. oncology products by revenue in 2016
- Premium Statistic Revenue from pharmaceutical manufacturer in Denmark 2009-2023
- Basic Statistic Members of EFPIA's pharmaceutical production value 1990-2022
- Premium Statistic Sales revenue distribution of JW Pharmaceutical South Korea 2022, by channel
- Premium Statistic Sales expenses of selected Chinese pharma companies 2021-2022
- Premium Statistic Sold packaging units of phytopharmaceuticals in Germany in 2022, by sales channel
- Premium Statistic Italy: number of R&D employees of biotech pharma companies 2014-2017
- Premium Statistic Biopharmaceutical market size forecast Japan 2011-2020
- Premium Statistic Revenue of the top ten pharmaceutical companies in France 2021
- Premium Statistic Mexico: pharmaceutical production 2017-2022
Related statistics
10
- Basic Statistic Number of employees of pharmaceutical companies by region France 2020
- Basic Statistic Total revenue of the French drug market worldwide 2010-2018
- Premium Statistic Number of companies in the pharmaceutical industry in France 1970-2018
- Basic Statistic Breakdown of employees of drug companies by age France 2014
- Premium Statistic Average full-time equivalent workforce of Boiron Laboratories 2012-2022
- Premium Statistic Net investments of Boiron laboratories 2014-2022
- Premium Statistic Boiron's stock price at the end of the year 2012-2022
- Premium Statistic Personnel costs of Boiron laboratories 2012-2022
- Premium Statistic Cashflow of Boiron laboratories 2013-2022
- Premium Statistic Boiron laboratories' market capitalization at the end of the year 2012-2022
Further related statistics
10
- Merck & Co total assets 2009-2023
- Merck & Co - expenditure on research and development 2006-2023
- M&A capacities - changes for the global pharma industry 2008-2015
- Merck & Co cash dividends declared 2006-2023
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Celgene's revenue and net income 2006-2018
- Sales of Johnson & Johnson 2006-2023 by region
- Revenue of Sinopharm 2011-2022, by category
- Annual revenue of Shanghai Pharmaceuticals 2011-2022
Further Content: You might find this interesting as well
Statistics
- Merck & Co total assets 2009-2023
- Merck & Co - expenditure on research and development 2006-2023
- M&A capacities - changes for the global pharma industry 2008-2015
- Merck & Co cash dividends declared 2006-2023
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Celgene's revenue and net income 2006-2018
- Sales of Johnson & Johnson 2006-2023 by region
- Revenue of Sinopharm 2011-2022, by category
- Annual revenue of Shanghai Pharmaceuticals 2011-2022
Ipsen. (February 13, 2020). Total assets of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros) [Graph]. In Statista. Retrieved May 08, 2024, from https://www.statista.com/statistics/1072979/ipsen-total-assets-french-company/
Ipsen. "Total assets of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros)." Chart. February 13, 2020. Statista. Accessed May 08, 2024. https://www.statista.com/statistics/1072979/ipsen-total-assets-french-company/
Ipsen. (2020). Total assets of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros). Statista. Statista Inc.. Accessed: May 08, 2024. https://www.statista.com/statistics/1072979/ipsen-total-assets-french-company/
Ipsen. "Total Assets of The French Pharmaceutical Group Ipsen from 2014 to 2019 (in Million Euros)." Statista, Statista Inc., 13 Feb 2020, https://www.statista.com/statistics/1072979/ipsen-total-assets-french-company/
Ipsen, Total assets of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros) Statista, https://www.statista.com/statistics/1072979/ipsen-total-assets-french-company/ (last visited May 08, 2024)
Total assets of the French pharmaceutical group Ipsen from 2014 to 2019 (in million euros) [Graph], Ipsen, February 13, 2020. [Online]. Available: https://www.statista.com/statistics/1072979/ipsen-total-assets-french-company/